TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells $6,866,240.40 in Stock

TransMedics Group, Inc. (NASDAQ:TMDX) insider Tamer I. Khayal sold 63,260 shares of TransMedics Group stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $108.54, for a total value of $6,866,240.40. Following the completion of the transaction, the insider now owns 9,792 shares of the company’s stock, valued at approximately $1,062,823.68. The sale was disclosed in a document filed with the SEC, which is available at this link.

TransMedics Group Trading Up 2.9 %

TransMedics Group stock opened at $127.99 on Monday. The firm has a 50-day moving average price of $85.54 and a two-hundred day moving average price of $77.32. TransMedics Group, Inc. has a 52-week low of $36.42 and a 52-week high of $129.66. The firm has a market capitalization of $4.19 billion, a price-to-earnings ratio of -376.44 and a beta of 1.87. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.40. TransMedics Group had a positive return on equity of 8.29% and a negative net margin of 3.43%. The business had revenue of $96.90 million during the quarter, compared to the consensus estimate of $83.78 million. During the same period in the previous year, the firm posted ($0.08) earnings per share. The business’s revenue was up 132.9% on a year-over-year basis. Sell-side analysts expect that TransMedics Group, Inc. will post 0.62 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on TMDX shares. TD Cowen lifted their price objective on shares of TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Piper Sandler reaffirmed an “overweight” rating and issued a $120.00 price target (up from $95.00) on shares of TransMedics Group in a report on Wednesday, May 1st. Canaccord Genuity Group increased their price objective on shares of TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. Morgan Stanley lifted their target price on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 28th. Finally, Oppenheimer increased their price target on TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 1st. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $119.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Venturi Wealth Management LLC bought a new stake in shares of TransMedics Group during the first quarter valued at about $30,000. Fidelis Capital Partners LLC acquired a new stake in shares of TransMedics Group in the 1st quarter worth approximately $35,000. Cutler Group LLC CA boosted its holdings in shares of TransMedics Group by 600.0% in the third quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock valued at $38,000 after acquiring an additional 600 shares in the last quarter. RiverPark Advisors LLC acquired a new position in shares of TransMedics Group during the third quarter valued at approximately $60,000. Finally, First Horizon Advisors Inc. raised its holdings in TransMedics Group by 26.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock worth $83,000 after purchasing an additional 222 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.